Tags

Type your tag names separated by a space and hit enter

[A new levodopa benserazide preparation for Parkinson's disease with motor fluctuations refractory to standard L-dopa].
Medicina (B Aires). 1991; 51(6):561-7.M

Abstract

As Parkinson's disease worsens, many patients develop motor fluctuations which usually correlate directly or indirectly with L-dopa plasma levels. A new L-dopa-benserazide HBS preparation (Madopar) a control release pharmaceutical formulation which is activated when it contacts gastric fluid thus providing more stable L-dopa plasma levels, was assayed. Ten patients with a diagnosis of idiopathic Parkinson's disease and motor fluctuations otherwise unresponsive to conventional therapy were selected. The average age was 62 years and the duration of the disease 9 years. The motor status was evaluated on an hourly basis with the King's College Parkinson's disease rating scale; in addition, a nocturnal disability scale (Lees) was used. Out of the 10 patients, 2 dropped out within the first month due to worsening of parkinsonian signs, while 7 of the remainders preferred HBS preparation to the previous treatment. The number of off hours in this group was reduced by 58% and motor fluctuation became less severe. In only 3 cases was it possible to use HBS as monotherapy while in the rest standard L-dopa had to be added, specially as morning doses. The average L-dopa daily dose was increased by 36%. Unwanted effects included psychiatric disturbances in two (in one L-dopa dose had to be reduced) and epigastralgia in one. Our findings suggest that this L-dopa-benserazide control release may be considered an able therapeutic formulation in the control of motor fluctuations in Parkinson's disease.

Authors+Show Affiliations

División Neurología, Hospital de Clínicas José de San Martín, Facultad de Medicina, Universidad de Buenos Aires, Argentina.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
English Abstract
Journal Article

Language

spa

PubMed ID

7476112

Citation

Fernández Pardal, M M., et al. "[A New Levodopa Benserazide Preparation for Parkinson's Disease With Motor Fluctuations Refractory to Standard L-dopa]." Medicina, vol. 51, no. 6, 1991, pp. 561-7.
Fernández Pardal MM, Gatto E, Micheli F, et al. [A new levodopa benserazide preparation for Parkinson's disease with motor fluctuations refractory to standard L-dopa]. Medicina (B Aires). 1991;51(6):561-7.
Fernández Pardal, M. M., Gatto, E., Micheli, F., Casas Parera, I., & Diaz, S. (1991). [A new levodopa benserazide preparation for Parkinson's disease with motor fluctuations refractory to standard L-dopa]. Medicina, 51(6), 561-7.
Fernández Pardal MM, et al. [A New Levodopa Benserazide Preparation for Parkinson's Disease With Motor Fluctuations Refractory to Standard L-dopa]. Medicina (B Aires). 1991;51(6):561-7. PubMed PMID: 7476112.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [A new levodopa benserazide preparation for Parkinson's disease with motor fluctuations refractory to standard L-dopa]. AU - Fernández Pardal,M M, AU - Gatto,E, AU - Micheli,F, AU - Casas Parera,I, AU - Diaz,S, PY - 1991/1/1/pubmed PY - 1991/1/1/medline PY - 1991/1/1/entrez SP - 561 EP - 7 JF - Medicina JO - Medicina (B Aires) VL - 51 IS - 6 N2 - As Parkinson's disease worsens, many patients develop motor fluctuations which usually correlate directly or indirectly with L-dopa plasma levels. A new L-dopa-benserazide HBS preparation (Madopar) a control release pharmaceutical formulation which is activated when it contacts gastric fluid thus providing more stable L-dopa plasma levels, was assayed. Ten patients with a diagnosis of idiopathic Parkinson's disease and motor fluctuations otherwise unresponsive to conventional therapy were selected. The average age was 62 years and the duration of the disease 9 years. The motor status was evaluated on an hourly basis with the King's College Parkinson's disease rating scale; in addition, a nocturnal disability scale (Lees) was used. Out of the 10 patients, 2 dropped out within the first month due to worsening of parkinsonian signs, while 7 of the remainders preferred HBS preparation to the previous treatment. The number of off hours in this group was reduced by 58% and motor fluctuation became less severe. In only 3 cases was it possible to use HBS as monotherapy while in the rest standard L-dopa had to be added, specially as morning doses. The average L-dopa daily dose was increased by 36%. Unwanted effects included psychiatric disturbances in two (in one L-dopa dose had to be reduced) and epigastralgia in one. Our findings suggest that this L-dopa-benserazide control release may be considered an able therapeutic formulation in the control of motor fluctuations in Parkinson's disease. SN - 0025-7680 UR - https://www.unboundmedicine.com/medline/citation/7476112/[A_new_levodopa_benserazide_preparation_for_Parkinson's_disease_with_motor_fluctuations_refractory_to_standard_L_dopa]_ L2 - https://medlineplus.gov/movementdisorders.html DB - PRIME DP - Unbound Medicine ER -